A Characterization of the Effects of Minocycline Treatment during Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders
Author(s):
Romero Miguel, Diego; Casquero-Veiga, Marta; MacDowell, Karina S.; Torres Sánchez, Sonia; García Partida, José Antonio; Lamanna Rama, Nicolás; Romero Miranda, Ana; Berrocoso, Esther; Leza, Juan C.; Desco Menéndez, Manuel; Soto-Montenegro, María Luisa
Publisher:
OUP
Issued date:
2021-09
Citation:
Romero-Miguel, D., Casquero-Veiga, M., MacDowell, K. S., Torres-Sanchez, S., Garcia-Partida, J. A., Lamanna-Rama, N., Romero-Miranda, A., Berrocoso, E., Leza, J. C., Desco, M., & Soto-Montenegro, M. L. (2021). A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders. In International Journal of Neuropsychopharmacology (Vol. 24, Issue 9, pp. 734–748). Oxford University Press (OUP).
ISSN:
1461-1457
xmlui.dri2xhtml.METS-1.0.item-contributor-funder:
Comunidad de Madrid
European Commission
Ministerio de Economía y Competitividad (España)
Ministerio de Ciencia, Innovación y Universidades (España)
Universidad Carlos III de Madrid
Sponsor:
M.L.S. was supported by the Ministerio de Ciencia, Innovación y
Universidades, Instituto de Salud Carlos III (projects PI14/00860
and PI17/01766, and grant CPII14/00005), co-financed by European
Regional Development Fund (ERDF), “A way of making Europe”,
CIBER of Mental Health (CIBERSAM), Delegación del Gobierno
para el Plan Nacional sobre Drogas (2017/085), Fundación
Mapfre and Fundación Alicia Koplowitz. M.C.-V. was supported
by Fundación Tatiana Pérez de Guzmán el Bueno. D.R.-M. was
supported by Consejería de Educación e Investigación,
Comunidad de Madrid, co-funded by European Social Fund
“Investing in your future” (grant, PEJD-2018-PRE/BMD-7899).
N.L.-R. was supported by Instituto de investigación Sanitaria
Gregorio Marañón. A.R.-M. was supported by Consejería de
Educación e Investigación, Comunidad de Madrid, co-funded
by European Social Fund “Investing in your future” (grant,
PEJ15/BIO/TL-0216). The CNIC was supported by the Spanish
Ministerio de Ciencia, Innovación y Universidades (MCIU) and
the Pro-CNIC Foundation. J.C.L. was supported by the Spanish
Ministry of Economy, Industry and Competitiveness (MINECOEU-
FEDER) SAF2016-75500-R and CIBERSAM. E.B.D., S.T.-S., and
J.A.G.-P. were supported by grants: co-financed by the “Fondo
Europeo de Desarrollo Regional” (FEDER)-UE “A way to build
Europe” from the “Ministerio de Economía y Competitividad”
(MINECO: RTI2018-099778-B-I00) and the “Ministerio de Salud-
Instituto de Salud Carlos III (PI18/01691); from the “Plan Nacional
sobre Drogas, Ministerio de Sanidad, Consumo y Bienestar
Social” (2019I041); from the “Programa Operativo de Andalucía
FEDER, Iniciativa Territorial Integrada ITI 2014–2020 Consejería
Salud, Junta de Andalucía” (PI-0080-2017 and PI-0009-2017); from
the Consejería de Salud de la Junta de Andalucía (PI-0134-2018);
from the University of Cádiz (PR2019-046); from the “Instituto
de Investigación e Innovación en Ciencias Biomédicas de
Cádiz-INiBICA” (IN-C22; LI19/06IN-CO22); from the “Consejería
de Economía, Innovación, Ciencia y Empleo de la Junta de
Andalucía” (CTS-510); from the “CIBERSAM” (CB/07/09/0033).
Project:
Gobierno de España. Proyecto PI14/00860. Grant CPII14/00005
Universidad Carlos III de Madrid. Proyecto PI17/01766. Grant CPII14/00005
Comunidad de Madrid. PEJD-2018-PRE/BMD-7899
Comunidad de Madrid. PEJ15/BIO/TL-0216
Gobierno de España. SAF2016-75500-R
Gobierno de España. RTI2018-099778-B-I00
Universidad Carlos III de Madrid. PI18/01691
Gobierno de España. 2019I041
Keywords:
Fdg-pet
,
Inflammatory/oxidonitrosative stress
,
Minocycline
,
Poly I:C
,
Schizophrenia
Rights:
© The Author(s) 2021. Published by Oxford University Press on behalf of CINP.
Atribución-NoComercial 3.0 España
Abstract:
Background: Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatme
Background: Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model.
Methods: On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35-49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue.
Results: MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions: MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2-ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.
[+]
[-]
Show full item record
Impact: